First-in-Class Oral Neuroplastogen Pioneer  ·  Clinical Stage

A patented oral neuroplastogen
for alcohol use disorder.

DMX-1001 is an investigational new chemical entity with granted composition-of-matter and method-of-use patents, a completed Phase 1a MAD trial, and an active Phase 1b program targeting the 29 million Americans living with AUD.

View Progress Investor Relations
Our Mission

Transforming treatment for addiction & neuropsychiatric disorders.

At DemeRx, we pioneer neuroplastogen medicines that restore brain health and break the cycle of addiction — advancing disease-modifying therapies across substance use disorders, mood disorders, and other CNS conditions.

— DMX-1001 · oral noribogaine · investigational
Clinical Progress
✓
Complete
Phase 1a MAD Trial

Multiple Ascending Dose trial of DMX-1001 complete — favorable safety and PK profile confirmed.

TrialPhase 1a · MAD
EndpointSafety & PK
✓
Accepted
IND Accepted for AUD

FDA IND for DMX-1001 in AUD accepted April 2026 — regulatory path to Phase 2 cleared.

FilingIND · DMX-1001
IndicationAlcohol Use Disorder
●
Active
Phase 1b Trial Underway

Active trial evaluating PK, PD, and safety of DMX-1001 in healthy volunteers.

TrialPhase 1b · PK/PD
SubjectsHealthy volunteers
◈
Granted
Core IP Portfolio

Granted patents covering composition of matter, methods of use, combinations, and formulations protect DMX-1001.

PatentsComposition · methods
CoverageFormulations · combinations
29M
Americans with AUD
<5%
Currently using medication
80%
Relapse rate within 1 year
$250B
Annual economic burden
Investor Relations →
Why DMX-1001 — The Science

Addiction is a chronic, relapsing disease of brain circuitry — not a failure of willpower. DMX-1001 is oral noribogaine, the active metabolite of ibogaine, engineered to deliver the neuroplastic benefit of the ibogaine class without the hallucinogenic, cardiac, or deliverability liabilities that have held it back.

01 — The Disease

Addiction is a brain disorder

Alcohol use disorder is a chronic, relapsing condition rooted in dysregulated reward and stress circuitry. Chronic exposure rewires synaptic connections, blunts dopaminergic signaling, and amplifies stress-driven craving. DMX-1001 is designed to act on the underlying neurobiology — not just the behavior.

Disease-modifying intent
02 — The Target

Structural neuroplasticity

Noribogaine targets structural neuroplasticity in the brain's addiction circuitry, promoting the rewiring associated with durable recovery — without the euphoric or addictive properties of conventional psychedelics or opioids.

Non-hallucinogenic neuroplastogen
03 — The Molecule

Oral, controlled, patented

DMX-1001 is an oral new chemical entity formulated for controlled, repeatable dosing — a fit for real-world AUD treatment and a conventional clinical and commercial path. Granted composition-of-matter, methods, formulations, and combinations patents protect it.

Phase 1a PK confirmed
04 — The Safety

Cardiac safety, addressed

The ibogaine class carries known cardiac considerations. Phase 1a MAD confirmed a favorable safety and tolerability profile for DMX-1001, with cardiology oversight led at board level by Pascal Goldschmidt, MD, former Dean of the University of Miami Miller School of Medicine.

Board-level cardiology oversight
05 — Pipeline in a Drug

One molecule, expanding indications

DMX-1001 is a platform: AUD is the lead indication, with pipeline expansion into opioid and cocaine use disorder, and adjacent CNS conditions including mood. One oral neuroplastogen, a pipeline of opportunities.

AUD lead · OUD · cocaine · CNS
Explore the full science → Mechanism · clinical evidence · IP · references
Why AUD

The unmet need is real. The path is proven.
The market is ready.

NIAAA · National Institutes of Health
In any given year, less than 10 percent of individuals diagnosed with alcohol use disorder receive treatment, and many of them do not receive the type of care that best fits their needs.
— George F. Koob, PhD · Director, NIAAA
01
The unmet need

A treatment gap measured in millions.

~80% of patients relapse within a year. Only three medications are FDA-approved for AUD — disulfiram, naltrexone, and acamprosate — and fewer than 2% of adults with AUD receive any of them. NIAAA itself acknowledges that "many individuals show only limited or no response" to current options.

29MU.S. adults
with AUD
<2%Receive
medication
3Approved
meds
02
The proven FDA path

An established regulatory pathway.

Three medicines have already cleared the FDA for AUD. The agency understands the disease, validated endpoints exist, and the regulatory framework is in place. DMX-1001 doesn't need to forge new ground — it follows a proven path with a differentiated mechanism.

Validated endpoints · regulatory precedent
03
The cleanest, fastest market

The most efficient path to first revenue.

A clearly defined patient population, validated efficacy endpoints, and established prescribing channels in primary care and addiction medicine — paired with an FDA actively soliciting new entrants. AUD is the most efficient first commercial indication for a neuroplastogen platform; OUD, cocaine, and adjacent CNS follow.

Lead indication · platform follows
Catalysts & The Raise
Jan 2026
Phase 1a MAD trial — safety & PK confirmed
✓ De-risked
Apr 2026
FDA IND accepted — DMX-1001 in AUD
✓ Regulatory path cleared
[Target: Q_ 20__]
Phase 1b PK/PD readout — healthy volunteers
● Active · next catalyst
Planned
Phase 2 proof-of-concept — alcohol use disorder
○ This round enables
Pipeline
Expansion — opioid & cocaine use disorder
○ Preclinical · platform upside
Current Financing
Raising $30M
Series B
  • Complete the active Phase 1b PK/PD trial
  • Initiate Phase 2 proof-of-concept in AUD
  • Advance CMC, formulation & the granted IP portfolio
  • Extend DMX-1001 into opioid & cocaine use disorder
Expected to fund operations through Phase 2 readiness. Detailed materials available to qualified investors under NDA.
Request the Data Room
Investor Relations

Clinical-stage.
Patent-protected.
Actively enrolling.

DemeRx is advancing DMX-1001 through a rigorous clinical development program. This section provides current program status, pipeline, press releases, and direct IR contact.

Phase 1a — Complete
IND — Accepted
Phase 1b — Active
IP Portfolio — Granted
NIH Grant — $1.7M
Clinical & Preclinical Pipeline
Asset / Indication Preclinical Phase 1a Phase 1b Phase 2 Phase 3
DMX-1001
Alcohol Use Disorder
Oral noribogaine · NCE
Complete
Active
Planned
DMX-1001
Opioid Use Disorder
Oral noribogaine · NCE
Planned
DMX-1001
Cocaine Use Disorder
Oral noribogaine · NCE
Planned
Media Coverage
Analysis · BioCentury
Trump's psychedelic order tests review norms — DemeRx noted as ibogaine-shift case
April 21, 2026
Subscription required
Investor Materials
Corporate Presentation

Request the
investor deck.

Our corporate presentation covers program status, preclinical and clinical data, IP position, market opportunity, and team credentials. Available to qualified investors under NDA.

Request Deck Contact IR
29M
U.S. patients with AUD
$250B
Annual economic burden
<5%
Currently use medication
4+
Granted patent families
Leadership, Board & Advisors

DemeRx is led by the scientist who pioneered noribogaine and holds its foundational patents, backed by a board that pairs drug-development and commercial experience with dedicated cardiology and psychiatry oversight.

Deborah Mash
Deborah C. Mash, PhD
CEO, President & Founder
Mark Ellison
Mark Ellison, PhD
President, Clinical Operations & Chief Development Officer
E. Douglas Kramer
E. Douglas Kramer, MD
VP, Clinical & Regulatory Affairs
Michael Snitkovsky
Michael Snitkovsky
Strategic Advisor
John C. Thomas Jr.
John C. Thomas Jr.
Chief Financial Officer & Secretary
Board of Directors
Richard Serbin
Richard S. Serbin, Esq.
Executive Chairman
Christopher Hassan
Christopher Hassan
Board Chairperson
Pascal Goldschmidt
Pascal J. Goldschmidt, MD
Director · Lead Consultant, Cardiology
Heather Callander-Potters
Heather Callander-Potters, MBA
Director
Guy Bolton
Guy Bolton
Director
Vitaly M. Pirotsky
Vitaly M. Pirotsky
Director
Scientific & Strategic Advisors
Bryon Adinoff
Bryon Adinoff, MD
Lead Consultant, Psychiatry
Matthew Buckley
Matthew ‘Whiz’ Buckley
Board Advisor
Hans Hertell
Amb. Hans Hertell
Board Advisor
Contact Investor Relations
Chief Financial Officer
John C. Thomas Jr.
Chief Financial Officer and Secretary
DemeRx, Inc.
Emailir@demerx.com Webdemerx.com
Chief Executive Officer & Founder
Deborah C. Mash, PhD
CEO, President & Founder · 30+ years noribogaine research · Original patent holder
Emaildmash@demerx.com LinkedInlinkedin.com/company/demerx-inc
ℹ

For institutional investors and qualified purchasers: DemeRx is a private clinical-stage company. Securities information is provided only to accredited investors under applicable securities laws. Media inquiries: media@demerx.com